ZYUS Life Sciences (TSE:ZYUS) has released an update.
ZYUS Life Sciences, a Canadian life sciences company, has received approval from Health Canada to begin a proof-of-concept trial for Trichomylin softgel capsules, which are aimed at treating moderate to severe cancer-related pain. This trial is a critical step towards de-risking the company’s upcoming Phase 2 clinical trial and advancing non-opioid pain management solutions.
For further insights into TSE:ZYUS stock, check out TipRanks’ Stock Analysis page.
